Business
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced two poster presentations at the European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 2025, in Amsterdam, Netherlands and virtually. The presentation details are as follows: Abstract Title: Rademikibart in Moderate-to-Severe Asthma: Impact of Eosinophils and Regional Differences on ResponsePoster Number: PA2480Presenter: Raúl Collazo, Ph.D.Session#218: Biologics for Asthma and Allergic Rhinitis: Novel Trial DataDate and Time: Monday, September 29th from 8:00 a.m. – 9:30 a.m. CET Abstract Title: Rapid and Sustained FEV1 Improvements with Rademikibart in Type 2 Asthma: Impact of Eosinophils and FENOPoster Number: PA2481Presenter: Raúl Collazo, Ph.D.Session#218: Biologics for Asthma and Allergic Rhinitis: Novel Trial DataDate and Time: Monday, September 29th from 8:00 a.m. – 9:30 a.m. CET Following the presentations, each presentation will be available on Connect’s website under the presentations and publications section. About RademikibartRademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the T helper 2 (Th2) inflammatory pathway to achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma. About Connect BiopharmaConnect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect also has an exclusive license and collaboration agreement for rademikibart with Simcere in China. For more information visit www.connectbiopharma.com. Forward-Looking Statem...